Pfizer said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate cancer treatment combination.
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo July 22 ...
July 22 (Reuters) - Pfizer said on Wednesday the U.S. Food and Drug Administration has granted priority review to its application seeking expanded approval for its prostate cancer treatment ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral ...
Pfizer (PFE) announced on Thursday that its oral Janus kinase inhibitor Litfulo reached the main goals in two late-stage trials for nonsegmental vitiligo, an autoimmune condition characterized by ...
Pfizer said Wednesday the Food and Drug Administration accepted for priority review its supplemental application seeking to expand the use of its prostate cancer treatment Talzenna in combination with ...
Federal regulators have granted accelerated approval to a novel therapy for advanced melanoma—giving doctors another weapon ...
The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) for attention-deficit/hyperactivity disorder (ADHD) in ...
The FDA has granted full approval for selpercatnib in the treatment of advanced cancer among patients ages 2 and older who carry a rare genetic alteration. Selpercatinib, also known as Retevmo, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results